Quality of life QoL results from the phase 3 REVEL study of ramucirumab docetaxel RAM DTX versus placebo docetaxel PL DTX in advanced metastatic NSCLC patients pts with progression after platinum based chemotherapy
Bildiriler · 2014
Yazarlar: EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, Tuncay GÖKSEL, T Park, V Gorbunova, RD Kowalyszyn, J Pikiel, G Czyzewicz, SV Orlov, CR Lewanski, M Thomas, P Bidoli, S Dakhil, S Gans, JH Kim, A Grigorescu, N Karaseva, S Yurasov, A Zimmerman, GC Carter, M Reck, F Cappuzzo, M Perol
Annual Congress of the European Society For Medical Oncology, İspanya, Uluslararası, 2014-2014